Amikacin-induced acute kidney injury in mechanically ventilated critically ill patients with sepsis

References

• Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016; 315(8):801–810.
   PubMed Web of Science ®Google Scholar
• Fleischmann-Struzek C, Mellhammar L, Rose N, et al. Incidence and mortality of hospital- and ICU-treated sepsis: results from an updated and expanded systematic review and meta-analysis. Intensive Care Med. 2020; 46(8):1552–1562.
   PubMed Web of Science ®Google Scholar
• Seymour CW, Gesten F, Prescott HC, et al. Time to treatment and mortality during mandated emergency care for sepsis. N Engl J Med. 2017; 376(23):2235–2244.
   PubMed Web of Science ®Google Scholar
• Karam G, Chastre J, Wilcox MH, et al. Antibiotic strategies in the era of multidrug resistance. Crit Care. 2016; 20(1):136.
   PubMed Web of Science ®Google Scholar
• Karabay O, Baştuğ A, Öztürk R, et al. Antibiotic consumption, resistance data, and prevention strategies. Mediterr J Infect Microbes Antimicrob. 2018;2018(7):7–35.
   Google Scholar
• Yüce A, Yapar N, Eren Kutsoylu O. Evaluation of antibiotic resistance patterns of Pseudomonas aeruginosa and Acinetobacter spp. strains isolated from intensive care patients between 2000–2002 and 2003–2006 periods in Dokuz Eylul University Hospital, Izmir. Mikrobiyol Bul. 2009; 43(2):195–202.
   PubMed Web of Science ®Google Scholar
• Boyer A, Gruson D, Bouchet S, et al. Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk. Drug Saf. 2013; 36(4):217–230.
   PubMedGoogle Scholar
• Martínez JA, Cobos-Trigueros N, Soriano A, et al. Influence of empiric therapy with a beta-lactam alone or combined with an aminoglycoside on prognosis of bacteremia due to gram-negative microorganisms. Antimicrob Agents Chemother. 2010; 54(9):3590–3596.
   PubMed Web of Science ®Google Scholar
• Paul M, Lador A, Grozinsky-Glasberg S, et al. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev. 2014; 2014(1):CD003344.
   PubMedGoogle Scholar
• Kumar A, Safdar N, Kethireddy S, et al. A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/meta-regression study. Crit Care Med. 2010; 38(8):1651–1664.
   PubMed Web of Science ®Google Scholar
• Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021; 47(11):1181–1247.
   PubMed Web of Science ®Google Scholar
• Oliveira JFP, Silva CA, Barbieri CD, et al. Prevalence and risk factors for aminoglycoside nephrotoxicity in intensive care units. Antimicrob Agents Chemother. 2009; 53(7):2887–2891.
   PubMed Web of Science ®Google Scholar
• Picard W, Bazin F, Clouzeau B, et al. Propensity-based study of aminoglycoside nephrotoxicity in patients with severe sepsis or septic shock. Antimicrob Agents Chemother. 2014; 58(12):7468–7474.
   PubMed Web of Science ®Google Scholar
• Llitjos J-F, Meslin S, Bredin S, et al. Aminoglycosides for the treatment of septic shock: a propensity-based study. Crit Care. 2020; 24(1):567.
   PubMed Web of Science ®Google Scholar
• Erbay A, Bodur H, Akinci E, et al. Evaluation of antibiotic use in intensive care units of a tertiary care hospital in Turkey. J Hosp Infect. 2005; 59(1):53–61.
   PubMed Web of Science ®Google Scholar
• van der Sluijs AF, van Slobbe-Bijlsma ER, Chick SE, et al. The impact of changes in intensive care organization on patient outcome and cost-effectiveness-a narrative review. J Intensive Care. 2017;5:13.
   PubMed Web of Science ®Google Scholar
• Maslove DM, Tang B, Shankar-Hari M, et al. Redefining critical illness. Nat Med. 2022; 28(6):1141–1148.
   PubMed Web of Science ®Google Scholar
• Wang Z, Weng J, Yang J, et al. Acute kidney injury-attributable mortality in critically ill patients with sepsis. PeerJ. 2022;10:e13184.
   PubMed Web of Science ®Google Scholar
• Uchino S, Kellum JA, Bellomo R, Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005; 294(7):813–818.
   PubMed Web of Science ®Google Scholar
• Liu J, Xie H, Ye Z, et al. Rates, predictors, and mortality of sepsis-associated acute kidney injury: a systematic review and meta-analysis. BMC Nephrol. 2020; 21(1):318.
   PubMed Web of Science ®Google Scholar
• Mehta RL, Cerdá J, Burdmann EA, et al. International society of nephrology’s 0by25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrology. Lancet (London, England). 2015; 385(9987):2616–2643.
   PubMed Web of Science ®Google Scholar
• Kellum JA, Lameire N, Aspelin P, et al. Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2:1–138.
   Web of Science ®Google Scholar
• Moore RD, Smith CR, Lipsky JJ, et al. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med. 1984;100(3):352–357.
   PubMed Web of Science ®Google Scholar
• Dewitte A, Joannès-Boyau O, Sidobre C, et al. Kinetic eGFR and novel AKI biomarkers to predict renal recovery. Clin J Am Soc Nephrol. 2015; 10(11):1900–1910.
   PubMed Web of Science ®Google Scholar
• Stanford ME. Health care aminoglycoside dosing guideline. 2017;1–8. Available from: http://med.stanford.edu/bugsanddrugs/dosing-protocols/_jcr_content/main/panel_builder/panel_0/download_2/file.res/Aminoglycoside%20Dosing%20Guide%202017-08-23.pdf.
   Google Scholar
• Tamma PD, Aitken SL, Bonomo RA, et al. Infectious diseases society of America 2022 guidance on the treatment of extended-spectrum β-lactamase producing enterobacterales (ESBL-E), carbapenem-resistant enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-Treat resistance (DTR-P. aeruginosa). Clin Infect Dis. 2022; 75(2):187–212.
   PubMed Web of Science ®Google Scholar
• Şirin MC, Ağuş N, Yilmaz N, et al. Yoğun bakim ünitelerinde yatan hastalarin kan kültürlerinden izole edilen mikroorganizmalar ve antibiyotik duyarliliklari. Turk Hij Den Biyol Derg. 2017;74(4):269–278.
   Google Scholar
• Boral B, Unaldi Ö, Ergin A, Acinetobacter Study Group, et al. A prospective multicenter study on the evaluation of antimicrobial resistance and molecular epidemiology of multidrug-resistant Acinetobacter baumannii infections in intensive care units with clinical and environmental features. Ann Clin Microbiol Antimicrob. 2019;18(1):19–19.
   PubMedGoogle Scholar
• Duszynska W, Taccone FS, Hurkacz M, et al. Therapeutic drug monitoring of amikacin in septic patients. Crit Care. 2013;17(4):R165.
   PubMed Web of Science ®Google Scholar
• Hassan NA, Awdallah FF, Abbassi MM, et al. Nebulized versus IV amikacin as adjunctive antibiotic for hospital and ventilator-acquired pneumonia postcardiac surgeries: a randomized controlled trial. Crit Care Med. 2018; 46(1):45–52.
   PubMed Web of Science ®Google Scholar
• Ruiz J, Ramirez P, Company MJ, et al. Impact of amikacin pharmacokinetic/pharmacodynamic index on treatment response in critically ill patients. J Glob Antimicrob Resist. 2018; 12:90–95.
   PubMed Web of Science ®Google Scholar
• Williams PJ, Hull JH, Sarubbi FA, et al. Factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin. J Clin Pharmacol. 1986; 26(2):79–86.
   PubMed Web of Science ®Google Scholar
• Bertino JSJ, Booker LA, Franck PA, et al. Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis. 1993; 167(1):173–179.
   PubMed Web of Science ®Google Scholar
• Zager RA. Endotoxemia, renal hypoperfusion, and fever: interactive risk factors for aminoglycoside and sepsis-associated acute renal failure. Am J Kidney Dis off J Natl Kidney Found. 1992; 20(3):223–230.
   PubMed Web of Science ®Google Scholar
• Humes HD. Aminoglycoside nephrotoxicity. Kidney Int. 1988; 33(4):900–911.
   PubMed Web of Science ®Google Scholar
• Lopez-Novoa JM, Quiros Y, Vicente L, et al. New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int. 2011; 79(1):33–45.
   PubMed Web of Science ®Google Scholar
• Boffa J-J, Arendshorst WJ. Maintenance of renal vascular reactivity contributes to acute renal failure during endotoxemic shock. J Am Soc Nephrol. 2005; 16(1):117–124.
   PubMed Web of Science ®Google Scholar
• Rigatto MH, Oliveira MS, Perdigão-Neto LV, et al. Multicenter prospective cohort study of renal failure in patients treated with colistin versus polymyxin B. Antimicrob Agents Chemother. 2016; 60(4):2443–2449.
   PubMed Web of Science ®Google Scholar
• Catry B, Cavaleri M, Baptiste K, et al. Use of colistin-containing products within the European union and European economic area (EU/EEA): development of resistance in animals and possible impact on human and animal health. Int J Antimicrob Agents. 2015; 46(3):297–306.
   PubMed Web of Science ®Google Scholar
• Rodrigues D, Baldissera GS, Mathos D, et al. Amikacin for the treatment of carbapenem-resistant Klebsiella pneumoniae infections: clinical efficacy and toxicity. Braz J Microbiol. 2021; 52(4):1913–1919.
   PubMed Web of Science ®Google Scholar
• Zhou Y-F, Tao M-T, Feng Y, et al. Increased activity of colistin in combination with amikacin against Escherichia coli co-producing NDM-5 and MCR-1. J Antimicrob Chemother. 2017; 72(6):1723–1730.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
   PubMedGoogle Scholar
• Talib S, Sharif F, Manzoor S, et al. Charlson comorbidity index for prediction of outcome of acute kidney injury in critically ill patients. Iran J Kidney Dis. 2017; 11(2):115–123.
   PubMed Web of Science ®Google Scholar
• Mabilat C, Gros MF, Nicolau D, et al. Diagnostic and medical needs for therapeutic drug monitoring of antibiotics. Eur J Clin Microbiol Infect Dis. 2020;39(5):791–797.
   PubMed Web of Science ®Google Scholar
• Sandaradura I, Alffenaar J-W, Cotta MO, et al. Emerging therapeutic drug monitoring of anti-infective agents in Australian hospitals: availability, performance and barriers to implementation. Br J Clin Pharmacol. 2022; 88(2):669–679.
   PubMed Web of Science ®Google Scholar
• Hagiya H, Otsuka F. Therapeutic drug monitoring for aminoglycosides: not yet readily available in Japanese university hospitals. JMA J. 2022; 5(1):127–129.
   PubMedGoogle Scholar